<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03957252</url>
  </required_header>
  <id_info>
    <org_study_id>APCaRI-05</org_study_id>
    <nct_id>NCT03957252</nct_id>
  </id_info>
  <brief_title>Validation of ClarityDX Prostate as a Reflex Test to Refine the Prediction of Clinically-significant Prostate Cancer</brief_title>
  <acronym>APCaRI-05</acronym>
  <official_title>Clinical Validation of ClarityDX Prostate as a Reflex Test to Prostate Specific Antigen (PSA) to Refine the Prediction of Clinically-significant Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nanostics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Alberta Prostate Cancer Research Initiative, APCaRI</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>DynaLIFE Medical Laboratories</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Prostate Cencer Centre, Calgary</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Northern Alberta Urology Centre</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Alberta Cancer Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Alberta Innovates Health Solutions</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Motorcycle Ride for Dad</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital Foundation - The Kaye Fund Competition</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Nanostics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to determine the accuracy of blood test ClarityDX Prostate to predict&#xD;
      the results of prostate biopsies in men who have PSA (Prostate Specific Antigen) greater than&#xD;
      3 and no higher than 10 ng/mL.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The main objective of this study is to validate ClarityDX Prostate as a reflex test to PSA to&#xD;
      refine the prediction of clinically-significant prostate cancer in a prospective cohort of&#xD;
      men to be recruited in Alberta, Whitehorse and in the United States of America when they are&#xD;
      scheduled for a biopsy as a result of on an elevated PSA.&#xD;
&#xD;
      This prospective training and validation cohort study will consist of up to 2,800 consenting&#xD;
      men in total, between ages 40-75 years old, without prior diagnosis of prostate cancer, who&#xD;
      have been selected to undergo a prostate biopsy to rule out prostate cancer.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 6, 2019</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Diagnostic Clinical Performance: prediction of clinically significant prostate cancer at biopsy</measure>
    <time_frame>3 years</time_frame>
    <description>For the first 1,400 patients, processed microflow cytometry data for each patient will be linked with patient clinical data to determine which patients have benign vs. aggressive prostate cancer.&#xD;
The models created during the Training Phase will be locked down and then used to determine the probability of approximately 1,400 patients in the investigational Validation Phase having clinically significant prostate cancer.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">2800</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Training Cohort</arm_group_label>
    <description>1400 men, 40-75 years old, without prior diagnosis of prostate cancer, who have been selected to undergo a prostate biopsy to rule out prostate cancer. Only patients with PSA greater than 3 ng/mL and no greater than 10ng/mL will be selected to have the ClarityDX Prostate test performed as a reflex test at DynaLIFE Medical Labs in Edmonton, Alberta.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Validation Cohort</arm_group_label>
    <description>Up to 1400 men, 40-75 years old, without prior diagnosis of prostate cancer, who have been selected to undergo a prostate biopsy to rule out prostate cancer. Only patients with PSA greater than 3 ng/mL and no greater than 10ng/mL will be selected to have the ClarityDX Prostate test performed as a reflex test at DynaLIFE Medical Labs in Edmonton, Alberta.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Blood test: ClarityDX Prostate</intervention_name>
    <description>Extracellular Vesicle profiling on patients who are suspected to have prostate cancer and will undergo a prostate biopsy. ClarityDX Prostate Risk Score will be compared with biopsy results to assess its predictive accuracy.</description>
    <arm_group_label>Training Cohort</arm_group_label>
    <arm_group_label>Validation Cohort</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Serum Separator Tube (SST) Serum&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        This prospective training and validation cohort study will consist of up to 2,800&#xD;
        consenting men in total (1,400 in the training cohort and up to 1,400 in the validation&#xD;
        cohort), between ages 40-75 years old, without prior diagnosis of prostate cancer, who have&#xD;
        been selected to undergo a prostate biopsy to rule out prostate cancer. Only patients with&#xD;
        PSA (Roche Cobas) greater than 3 ng/mL will be selected to have the ClarityDX Prostate test&#xD;
        performed as a reflex test at DynaLIFE.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Males between 40-75 years of age;&#xD;
&#xD;
          2. With and without family history of prostate cancer;&#xD;
&#xD;
          3. No prior prostate cancer diagnosis and who are referred to have a prostate biopsy;&#xD;
&#xD;
          4. PSA (Roche Cobas) results &gt; than 3ng/mL and collected within 6m of enrollment;&#xD;
&#xD;
          5. Willing to permit provincial agencies (e.g. Alberta Health Services, Alberta Health,&#xD;
             Netcare, Service Alberta) to disclose health-related information to study;&#xD;
&#xD;
          6. Undergoing a diagnostic prostate biopsy; and&#xD;
&#xD;
          7. Provided informed consent to participate in the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Unwilling to participate in the study;&#xD;
&#xD;
          2. Unavailable for biopsy procedure in recruitment areas;&#xD;
&#xD;
          3. Not undergoing a prostate biopsy;&#xD;
&#xD;
          4. Prior diagnosis of cancer excluding non-melanoma skin cancer; and/or&#xD;
&#xD;
          5. Under the age of 40 years of age or over the age of 75 years of age.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adrian S Fairey, MD, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northern Alberta Urology Centre, University of Alberta</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Matthew E Hyndman, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Southern Alberta Institute of Urology, University of Calgary</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Catalina Vasquez, MSc</last_name>
    <phone>1780-499-5396</phone>
    <email>catalina.vasquez@nanosticsdx.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Aditya Muley, MSc</last_name>
    <phone>+1 647-539-1845</phone>
    <email>aditya.muley@nanosticsdx.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Century Clinical Research Institute</name>
      <address>
        <city>Daytona Beach</city>
        <state>Florida</state>
        <zip>32117</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21218</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christian Pavlovich, MD</last_name>
    </contact>
    <investigator>
      <last_name>Christian Pavlovich, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Prostate Cancer Centre</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2V 1P9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Megan Balakas, RN, BSN, BS</last_name>
      <phone>1403-943-8953</phone>
      <email>megan.b@prostatecancercentre.ca</email>
    </contact>
    <investigator>
      <last_name>Matthew E Hyndman, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northern Alberta Urology Centre</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 1Z1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anais Martin, PhD</last_name>
      <phone>780-407-5668</phone>
      <email>amedinam@ualberta.ca</email>
    </contact>
    <investigator>
      <last_name>Adrian S Fairey, MD, MSC</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yukon</name>
      <address>
        <city>Whitehorse</city>
        <state>Yukon Territory</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sean Secord, MSc, RN</last_name>
      <email>sean.secord@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Russell Bamford, B.A, M.B</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>May 17, 2019</study_first_submitted>
  <study_first_submitted_qc>May 17, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 21, 2019</study_first_posted>
  <last_update_submitted>June 16, 2021</last_update_submitted>
  <last_update_submitted_qc>June 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ClarityDX Prostate</keyword>
  <keyword>Diagnosis</keyword>
  <keyword>Reflex Test</keyword>
  <keyword>Extracellular Vesicle</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 10, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/52/NCT03957252/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

